US 12,264,151 B2
Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof
Yihan Wang, Guangdong (CN); and Huanyin Li, Guangdong (CN)
Assigned to Shenzhen TargetRx, Inc., Guangdong (CN)
Filed by Shenzhen TargetRx, Inc., Guangdong (CN)
Filed on Oct. 25, 2022, as Appl. No. 17/973,182.
Application 17/973,182 is a continuation of application No. 16/971,128, granted, now 11,512,074, previously published as PCT/CN2019/080011, filed on Mar. 28, 2019.
Claims priority of application No. 201810262188.5 (CN), filed on Mar. 28, 2018.
Prior Publication US 2023/0138863 A1, May 4, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 405/14 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)
CPC C07D 405/14 (2013.01) [A61P 35/02 (2018.01); C07B 2200/05 (2013.01)] 15 Claims
 
1. A compound of formula (Φ), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, stereoisomer or isotopic variant thereof:

OG Complex Work Unit Chemistry
wherein,
R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23 and R24 are independently selected from hydrogen or deuterium;
X1 and X2 are independently selected from CH3, CD3, CHD2 or CH2D;
X3 is selected from CH2CH3, CH2CH2D, CH2CHD2, CH2CD3, CHDCH3, CHDCH2D, CHDCHD2, CHDCD3, CD2CH3, CD2CH2D, CD2CHD2 or CD2CD3;
Y1, Y2 and Y3 are independently selected from hydrogen or deuterium;
with the proviso that the compound contains at least one deuterium atom.